Tigen
Benjamin Gilgen is an experienced professional with a strong background in strategy, marketing, and innovation within various sectors, particularly in healthtech and biotech. Currently serving as a Member of the Board of Directors at MTIP since August 2024, Benjamin also heads Marketing and Innovation at Tigen, focusing on cell therapies for cancer treatment. As an advisor at Gilgen & Company AG, Benjamin partners with organizations to enhance their brand strategies. Prior roles include Partner at Prophet, Managing Director at MetaDesign, and Co-Founder of both Romazini fine wine and The Zurich Consulting Company. Additionally, Benjamin held managerial roles at Arthur D. Little and UBS. Benjamin holds a lic. oec. HSG degree in International Management from the University of St.Gallen and has additional education from the University of Geneva and Kantonsschule Solothurn.
Tigen
We are a clinical-stage biotech company in the field of cell therapies to cure cancer. We are a disruptive catalyst, combining a unique culture with a multidisciplinary set of world-class capabilities and a long-term perspective to the benefit of patients and society.